{"title":"Pembrolizumab May Enhance Current Treatments for Esophagogastric Cancers.","authors":"","doi":"10.1158/2159-8290.CD-RW2020-079","DOIUrl":null,"url":null,"abstract":"Anti-PD-1 was safe to add to anti-HER2 plus chemotherapy in HER2-positive esophagogastric cancers.","PeriodicalId":502270,"journal":{"name":"Cancer Discovery","volume":"3 2","pages":"901"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2159-8290.CD-RW2020-079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Anti-PD-1 was safe to add to anti-HER2 plus chemotherapy in HER2-positive esophagogastric cancers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
